Home>>CTOP (trifluoroacetate salt)

CTOP (trifluoroacetate salt) (Synonyms: Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr)

Catalog No.GC45415

 

Products are for research use only. Not for human use. We do not sell to patients.

CTOP (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
1mg
$170.00
In stock
5mg
$636.00
In stock
10mg
$1,103.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CTOP is a peptide antagonist of the μ-opioid receptor (IC50 = 2.8 nM).1 It is selective for μ-opioid receptors over δ-opioid receptors (IC50 = 13,500 nM) and somatostatin receptors (IC50 = 24,000 nM). CTOP inhibits the antinociceptive effect of morphine in the tail flick test in mice (ED50 = 0.018 nmol) and reverses morphine-induced increases in locomotor activity (ED50 = 0.02 nmol).2 It also induces withdrawal symptoms in a mouse model of chronic, but not acute, morphine dependence.

References
1. Pelton, J.T., Kazmierski, W., Gluya, K., et al. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ opioid receptors. Journal of Medicinal Chemistry 29(11), 2370-2375 (2013).
2. Gulya, K., KrivÁn, M., Nyolczas, N., et al. Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur. J. Pharmacol. 150(3), 355-360 (1988).

Reviews

Review for CTOP (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CTOP (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.